Bayer AG Sponsored ADR (BAYRY)
BAYRYs Cardiovascular Drug Hits Goals in Late-Stage Study
Bayer's asundexian hits key goals in the OCEANIC-STROKE study, showing reduced ischemic stroke risk without added major bleeding.
Bayer's stock is jumping on secondary stroke drug's trial success
Bayer stock jumped on Monday after the German healthcare company said a late-stage stroke drug trial achieved its goals.
Bayer shares up more than 8% on revived fortunes for blood thinner
Shares in Bayer jumped more than 8% on Monday after initial clinical trial results turned around the fortunes of a key cardiovascular drug that suffered a major development setback two years ago.
Bayer Sees Positive Results in Study for Asundexian as Stroke Treatment
The pharma company said asundexian, when combined with antiplatelet therapy, lowered the risk of stroke in patients during the study.
Bayer reports positive results for blood thinner after 2023 setback
German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU
Bayer BAYRY obtained European Commission approval for elinzanetant for the treatment of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) associated with menopause or caused by adjuvant endocrine therapy (AET) related to breast cancer.
Why Bayer Aktiengesellschaft (BAYRY) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Bayer Aktiengesellschaft (BAYRY) Q3 2025 Earnings Call Transcript
Bayer Aktiengesellschaft (OTCPK:BAYRY) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Jost Reinhard - Senior VP & Head of Investor Relations William Anderson - Chairman of the Management Board & CEO Wolfgang Nickl - CFO & Member of Management Board Stefan Oelrich - Head of the Pharmaceuticals Division & Member of the Board of Management Dave Tomasi - President of Bayer and Head of Comm. Ops. of Consumer Health, NA Rodrigo Santos - Member of Management Board & President of the Crop Science Division Conference Call Participants Thibault Boutherin - Morgan Stanley, Research Division Sachin Jain - BofA Securities, Research Division Richard Vosser - JPMorgan Chase & Co, Research Division Laurent Favre - BNP Paribas, Research Division Charles Pitman - Barclays Bank PLC, Research Division Christian Faitz - Kepler Cheuvreux, Research Division Florent Cespedes - Sanford C.
Bayer Q3 Earnings Beat Estimates on Crop Science Business Gains
Bayer's Q3 earnings surged on Crop Science strength, offsetting pricing and currency headwinds across divisions.
Bayer Posts Net Loss on Litigation Hit
Bayer's net loss narrowed in the third quarter but additional litigation provisions weighed on its crop-science business.
Bayer's third-quarter adjusted profit beats market view
Bayer said on Wednesday that third-quarter adjusted operating income gained 20.8%, citing gains at the Crop Science division and reconciliation effects in accounting.
Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year?
Here is how Bayer Aktiengesellschaft (BAYRY) and Biorestorative Therapies, Inc. (BRTX) have performed compared to their sector so far this year.
